Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct 29;16(6):1266-1278.
doi: 10.3390/neurolint16060096.

Efficacy of Nusinersen Treatment in Type 1, 2, and 3 Spinal Muscular Atrophy: Real-World Data from a Single-Center Study

Anna Lemska  1 , Piotr Ruminski  1 , Jakub Szymarek  1 , Sylwia Studzinska  2 , Maria Mazurkiewicz-Beldzinska  1
Affiliations

Efficacy of Nusinersen Treatment in Type 1, 2, and 3 Spinal Muscular Atrophy: Real-World Data from a Single-Center Study

Anna Lemska et al. Neurol Int. .

Abstract

Background: Spinal muscular atrophy (SMA) is an inherited neuromuscular disease characterized by progressive muscle weakness and atrophy due to the absence of the survival motor neuron 1 (SMN1) gene. SMA is classified into types 0 through 4 based on the age of symptom onset and the severity of motor function decline. Recent advances in SMA treatment, including nusinersen, onasemnogene abeparvovec, and risdiplam, have significantly improved the prognosis of SMA patients. This study evaluated the safety and efficacy of nusinersen in pediatric patients with SMA types 1, 2, and 3 in a real-world clinical setting.

Methods: This prospective observational single-center study assessed the treatment effects of nusinersen in 23 pediatric patients with genetically confirmed SMA over a 22-month observation period. All the participants received intrathecal loading doses of 12 mg of nusinersen on days 1, 14, 28, and 63, followed by maintenance doses every four months. Functional assessments were conducted using the CHOP-INTEND scale. Data were collected during routine patient visits, including clinical laboratory tests and vital sign parameters, and adverse events were recorded. The inclusion criteria were defined by the national reimbursement program for nusinersen treatment in Poland.

Results: Initially, 37 patients ranging from 1 month old to 18 years old were included, but 23 were ultimately observed due to changes in treatment regimens or assessment scales. The patients showed significantly improved CHOP-INTEND scores over the 22-month period. At 6 months, the average increase was 4.2 points, continuing to 17.8 points at 22 months. By the end of the study, 100% of patients showed either stabilization or improvement, with significant clinical improvements observed in several patients. Nusinersen was generally well-tolerated, with post-lumbar puncture headache and lower back pain being the most common adverse events.

Conclusions: Nusinersen treatment significantly enhances motor function in pediatric patients with SMA types 1, 2, and 3. This study demonstrates the importance of early and sustained treatment, with most patients showing the continuous improvement or stabilization of motor function. These findings support the use of nusinersen as an effective therapy for SMA; however, further research is needed to understand the long-term outcomes and optimize treatment strategies.

Keywords: motor function; nusinersen; real-world data; spinal muscular atrophy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Change in CHOP-INTEND score versus baseline.
Figure 2
Figure 2
Percentage of patients with confirmed stabilization or improvement versus baseline.
Figure 3
Figure 3
Change in CHOP-INTEND score versus baseline.
Figure 4
Figure 4
Change in CHOP-INTEND score versus baseline (SMA type 1).
Figure 5
Figure 5
Percentage of patients with confirmed stabilization or improvement versus baseline (SMA type 1).
Figure 6
Figure 6
Change in CHOP-INTEND score versus baseline (SMA type 2 and type 3).
Figure 7
Figure 7
Percentage of patients with confirmed stabilization or improvement versus baseline (SMA type 2 and 3).
See this image and copyright information in PMC

References

    1. Prior T.W., Leach M.E., Finanger E. Spinal Muscular Atrophy. In: Adam M.P., Feldman J., Mirzaa G.M., Pagon R.A., Wallace S.E., Bean L.J.H., Gripp K.W., Amemiya A., editors. Literature Cited. University of Washington, Seattle; Seattle, WA, USA: 2000. pp. 1993–2024. GeneReviews® [Internet] - PubMed
    1. Wirth B. An update of the mutation spectrum of the survival motor neuron gene (SMN1) in autosomal recessive spinal muscular atrophy (SMA) Hum. Mutat. 2000;15:228–237. doi: 10.1002/(SICI)1098-1004(200003)15:3<228::AID-HUMU3>3.0.CO;2-9. - DOI - PubMed
    1. Arnold W.D., Kassar D., Kissel J.T. Spinal muscular atrophy: Diagnosis and management in a new therapeutic era. Muscle Nerve. 2015;51:157–167. doi: 10.1002/mus.24497. - DOI - PMC - PubMed
    1. Kolb S.J., Kissel J.T. Spinal Muscular Atrophy. Neurol. Clin. 2015;33:831–846. doi: 10.1016/j.ncl.2015.07.004. - DOI - PMC - PubMed
    1. Calucho M., Bernal S., Alías L., March F., Venceslá A., Rodríguez-Álvarez F.J., Aller E., Fernández R.M., Borrego S., Millán J.M., et al. Correlation between SMA type and SMN2 copy number revisited: An analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases. Neuromuscul Disord. 2018;28:208–215. doi: 10.1016/j.nmd.2018.01.003. - DOI - PubMed

LinkOut - more resources